Nama's AI scorecard currently rates Acadia Healthcare Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ACHC's P/E ratio?

Acadia Healthcare trades at a trailing price-to-earnings ratio of 26.1.

When does ACHC report earnings?

Acadia Healthcare's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.33.

What is the ACHC price target?

The median analyst price target from 14 analysts is $32.50, with a range of $17.00 – $41.00.

Is ACHC Shariah compliant?

Nama's AAOIFI-style screen reads Acadia Healthcare as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Acadia Healthcare (ACHC)

Healthcare · Medical Care Facilities · NASDAQ

Acadia Healthcare (ACHC) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $3.44B, a trailing price-to-earnings ratio of 26.1 and a free-cash-flow yield of -13.1%. Over the most recent reported fiscal year, revenue grew 5.0%. Nama's AI scorecard rates it Sell, 3.2 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 3.2/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Middle · +44.3% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-58.8%

How far the last close sits under the highest price of the past five years.

Market cap	$3.44B
Trailing P/E	26.1
Price / book	1.7
Price / sales	1.0
FCF yield	-13.1%
Dividend yield	—
Gross margin	96.4%
Operating margin	10.1%
Net margin	-33.4%
Revenue growth (YoY)	+5.0%
Revenue growth (3-yr annual)	+8.3%
EPS growth (YoY)	-38.8%
FCF/share growth (YoY)	—
Beta	0.6
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Care Facilities

ACHC earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $0.33). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.60	$0.46	+30.4%	$895.31M
Q2 2026	Jul 28, 2026	$0.38	$0.35	+8.6%	$865.84M
Q1 2026	Apr 29, 2026	$0.37	$0.26	+42.3%	$828.80M
Q4 2025	Feb 25, 2026	$0.07	$0.01	+600.0%	$821.46M

ACHC analyst price target

Median target $32.50 from 14 analysts, ranging $17.00 – $41.00.

Medical Care Facilities peers

Ticker	Company	Market cap	P/E
HCA	HCA Healthcare	$103.40B	16.5
THC	Tenet Healthcare	$22.55B	12.7
EHC	Encompass Health	$13.50B	22.4
FMS	Fresenius Medical Care	$12.15B	10.2
DVA	DaVita	$12.04B	13.6
UHS	Universal Health Services	$11.52B	8.6
ENSG	Ensign Group	$10.56B	23.8
PACS	PACS Group	$7.87B	20.1

Explore live ACHC data on Nama Insights →

ACHC FAQ

Is ACHC a buy?: Nama's AI scorecard currently rates Acadia Healthcare Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ACHC's P/E ratio?: Acadia Healthcare trades at a trailing price-to-earnings ratio of 26.1.
When does ACHC report earnings?: Acadia Healthcare's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.33.
What is the ACHC price target?: The median analyst price target from 14 analysts is $32.50, with a range of $17.00 – $41.00.
Is ACHC Shariah compliant?: Nama's AAOIFI-style screen reads Acadia Healthcare as Not Shariah Compliant. At least one of the three ratios or the industry test failed.